Local blockade of allergic airway hyperreactivity and inflammation by the poxvirus-derived pan-CC-chemokine inhibitor vCCI

Allergen-induced asthma is characterized by chronic pulmonary inflammation, reversible bronchoconstriction, and airway hyperreactivity to provocative stimuli. Multiple CC-chemokines, which are produced by pulmonary tissue in response to local allergen challenge of asthmatic patients or experimentally sensitized rodents, chemoattract leukocytes from the circulation into the lung parenchyma and airway, and may also modify nonchemotactic function. To determine the therapeutic potential of local intrapulmonary CC-chemokine blockade to modify asthma, a recombinant poxvirus-derived viral CC-chemokine inhibitor protein (vCCI), which binds with high affinity to rodent and human CC-chemokines in vitro and neutralizes their biological activity, was administered by the intranasal route. Administration of vCCI to the respiratory tract resulted in dramatically improved pulmonary physiological function and decreased inflammation of the airway and the lung parenchyma. In contrast, vCCI had no significant effect on the circulating levels of total or allergen-specific IgE, allergen-specific cytokine production by peripheral lymph node T cells, or peritoneal inflammation after local allergen challenge, indicating that vCCI did not alter systemic Ag-specific immunity or chemoattraction at extrapulmonary sites. Together, these findings emphasize the importance of intrapulmonary CC-chemokines in the pathogenesis of asthma, and the therapeutic potential of generic and local CC-chemokine blockade for this and other chronic diseases in which CC-chemokines are locally produced.

IgA antibodies for diagnosis of acute congenital and acquired toxoplasmosis

An ELISA for IgA toxoplasma antibodies was positive in 12 pregnant women who seroconverted during gestation. Positive IgA titers were also noted in 10 individuals with biopsy-proven toxoplasmic lymphadenitis; the highest titers were noted in the first months following onset of clinical signs. Toxoplasma IgA antibodies were also demonstrable in 8 of 9 infants/fetuses with congenital toxoplasma infection. In some, IgM antibodies could not be demonstrated. Among 20 patients with AIDS and biopsy-proven toxoplasmic encephalitis, only 1 had IgA antibodies. None of 20 individuals with chronic toxoplasma infection had demonstrable IgA antibodies. Demonstration of IgA toxoplasma antibodies should be useful for diagnosis of recently acquired infection and for diagnosis of the infection in the fetus and newborn.

Detection of antigens in urine during acute toxoplasmosis

Toxoplasma antigens were detected in sera and urine of mice acutely infected with Toxoplasma gondii. The concentrations of antigens in the urine samples measured by enzyme-linked immunosorbent assay were similar to those detected in the sera of the corresponding mice. The major antigens were not dialyzable and were largely destroyed by treatment with trichloroacetic acid and heat (100 degrees C for 1 h). Toxoplasma antigens were demonstrable on Western blots (immunoblots) of the urine samples.

Diagnosis of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome by using a new serologic method

The present study was performed to develop a serological method for diagnosing toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome (AIDS). The trophozoite form of Toxoplasma gondii, fixed with either Formalin or acetone, was used in a modification of an agglutination method previously shown to differentiate between the acute and the chronic (latent) stages of infection with toxoplasma in immunologically normal persons. By using these antigens in separate tests and evaluating the data for statistical significance, 70% of patients with AIDS with biopsy-proven toxoplasmic encephalitis were distinguished from control, ambulatory patients with AIDS with toxoplasma antibodies but without signs or symptoms of central nervous system involvement. In a separate study, the agglutination tests identified from controls 84% of patients with AIDS with two or more brain lesions detected by computed-tomographic or magnetic-resonance-imaging scans and suspected of having toxoplasmic encephalitis. Thus, these agglutination tests should prove valuable for the noninvasive diagnosis of toxoplasmic encephalitis in patients with AIDS.